Protocol
Ara-290 (16 mg Vial)
Complete dosage protocol and reconstitution guide for Ara-290 (16 mg Vial).
Calculator preset
Run the vial math before tracking.
At 8 mg/mL, 1 unit = 0.08 mg (80 mcg) ; 4 mg = 50 units (0.50 mL) and 8 mg = 100 units (1.00 mL) on a U-100 syringe.
01 · At a glance
Quickstart Highlights
Ara-290 (also known as cibinetide) is a non-erythropoietic peptide derived from erythropoietin that engages the Innate Repair Receptor (IRR). Clinical studies commonly use once‑daily subcutaneous injections. Documented daily dose in human trials: 4 mg (subcutaneous) Dose-ranging studies have evaluated 1 mg, 4 mg, and 8 mg daily for 28 days Some ophthalmic trials used 4 mg daily for up to 12 weeks Reconstitute to a practical concentration for clear insulin‑syringe measurements Store lyophilized at freezer temperatures; refrigerate after reconstitution
02 · Dosing & reconstitution
Dosing & Reconstitution Guide
A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.
Standard / Gradual Approach (2 mL = 8 mg/mL)
in human trials: 4 mg (subcutaneous) Dose-ranging studies have evaluated 1 mg, 4 mg, and 8 mg daily for 28 days Some ophthalmic trials used 4 mg daily for up to 12 weeks Reconstitute to a practical concentration for clear insulin‑syringe measurements Store lyophilized at freezer temperatures; refrigerate after reconstitution
Advanced / Aggressive Approach
Reconstitution Steps
- Confirm the vial amount, unit, and diluent amount before entering values in the calculator.
- Add diluent slowly down the inner wall of the vial when reconstitution is appropriate for the compound.
- Swirl or roll gently until dissolved; avoid shaking unless the product instructions specifically say otherwise.
- Label the vial with the date and concentration, then store according to the protocol and product instructions.
03 · What you'll need
Supplies Needed
Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.
- Match the label on the vial before calculating.
- Use only the diluent appropriate for the compound and instructions.
- Calculator output can be translated to syringe units.
- Log dose dates, inventory, sites, and observations.
Protocol Overview
- Goal: Support small‑fiber nerve integrity and modulate inflammatory signaling
- Schedule: Once‑daily subcutaneous injections
- Dose Range: 4 mg/day is most commonly reported; dose‑ranging studies include 1 mg and 8 mg/day Duration: 4 weeks in neuropathy trials; up to 12 weeks in ophthalmic studies
- Reconstitution: 2.0 mL per 16 mg vial → 8 mg/mL for straightforward unit calculations
- Storage: Lyophilized at freezer temperatures; refrigerate reconstituted solution
Dosing Protocol
- in human trials: 4 mg (subcutaneous) Dose-ranging studies have evaluated 1 mg, 4 mg, and 8 mg daily for 28 days Some ophthalmic trials used 4 mg daily for up to 12 weeks Reconstitute to a practical concentration for clear insulin‑syringe measurements Store lyophilized at freezer temperatures; refrigerate after reconstitution
- If values change, rerun the calculator and update the protocol so future logs match the active plan.
Storage Instructions
- Review the source instructions and storage notes before handling any vial.
- Storage: Lyophilized at freezer temperatures; refrigerate reconstituted solution
- Keep mixed and unmixed items clearly labeled so inventory and dose logs stay accurate.
04 · Good to know
Important Notes
- This Ara-290 page is for educational research organization only.
- Confirm route, dose, contraindications, monitoring, storage, and cycle decisions with qualified professional guidance.
- Use sterile technique, rotate sites when applicable, and log missed doses, reactions, and inventory changes.
05 · How it works
How This Works
Ara-290 is an 11‑amino‑acid, non‑erythropoietic peptide derived from erythropoietin’s helix‑B region.
It binds the Innate Repair Receptor (a heteromer of EPO‑R and CD131), triggering cytoprotective and anti‑inflammatory pathways without stimulating red blood cell production.
Human trials have reported improvements in small‑fiber neuropathy symptom scales and objective measures of small‑fiber integrity, with dose‑ranging studies exploring 1–8 mg daily.
Some studies also explored metabolic and ophthalmic endpoints.
IRR activation: Shifts tissue milieu from pro‑inflammatory to pro‑repair signaling.
The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.
06 · Daily habits
Lifestyle Factors
- Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
- Track body metrics only if they are relevant to the user's goal and approved data sources.
- Use consistent timing and logging habits so adherence data is meaningful.
07 · What to expect
Potential Benefits & Side Effects
- Reported findings from clinical and preclinical research.
- Improvements in neuropathic symptom scores and functional measures in small‑fiber neuropathy cohorts Objective increases in small‑fiber metrics (e.g., corneal nerve fiber parameters) in some studies Generally well‑tolerated in trials; common events were mild and transient Possible mild effects: local injection‑site irritation, headache, transient fatigue
08 · Technique
Injection Technique
- Wash hands with soap and water.
- Wipe the vial stopper and chosen site with alcohol, then let both dry.
- Confirm the vial concentration, calculator result, and intended draw amount before loading the syringe.
- Use the route and needle technique directed by a qualified professional or product instructions.
- For subcutaneous injections, rotate sites and inject slowly to limit leakage and irritation.
- Do not reuse needles or syringes.
- Dispose of sharps in a puncture-resistant container.
- Return stored items promptly to the correct temperature.
- Log dose, site, date, time, inventory change, and any observation.
09 · Evidence